JP2019517463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517463A5 JP2019517463A5 JP2018559929A JP2018559929A JP2019517463A5 JP 2019517463 A5 JP2019517463 A5 JP 2019517463A5 JP 2018559929 A JP2018559929 A JP 2018559929A JP 2018559929 A JP2018559929 A JP 2018559929A JP 2019517463 A5 JP2019517463 A5 JP 2019517463A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxopyridin
- methoxypyridin
- methoxymethyl
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- 239000013078 crystal Substances 0.000 claims 19
- -1 3-Fluoro-4-methoxypyridin-2-yl Chemical group 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 239000002904 solvent Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1h-pyrazole-4-carboxamide Chemical compound NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 claims 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 7
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
- 230000001351 cycling effect Effects 0.000 claims 4
- 201000011190 diabetic macular edema Diseases 0.000 claims 4
- 206010019860 Hereditary angioedema Diseases 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 229910021653 sulphate ion Inorganic materials 0.000 claims 3
- 230000008728 vascular permeability Effects 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164519A JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344059P | 2016-06-01 | 2016-06-01 | |
| GB1609607.5 | 2016-06-01 | ||
| GBGB1609607.5A GB201609607D0 (en) | 2016-06-01 | 2016-06-01 | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| US62/344,059 | 2016-06-01 | ||
| PCT/GB2017/051579 WO2017208005A1 (en) | 2016-06-01 | 2017-06-01 | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1 -({4-[2-oxopyridin-1 -yl)methyl]phenyl} methyl) pyrazole -4-carboxamide as kallikrein inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164519A Division JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517463A JP2019517463A (ja) | 2019-06-24 |
| JP2019517463A5 true JP2019517463A5 (https=) | 2020-07-09 |
| JP6957516B2 JP6957516B2 (ja) | 2021-11-02 |
Family
ID=56410856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559929A Active JP6957516B2 (ja) | 2016-06-01 | 2017-06-01 | カリクレインインヒビターとしての、ｎ−［（３−フルオロ−４−メトキシピリジン−２−イル）メチル］−３−（メトキシメチル）−１−（｛４−［（２−オキソピリジン−１−イル）メチル］フェニル｝メチル）ピラゾール−４−カルボキサミドの多形体 |
| JP2021164519A Active JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164519A Active JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US11230537B2 (https=) |
| EP (2) | EP3464265B1 (https=) |
| JP (2) | JP6957516B2 (https=) |
| KR (1) | KR102425918B1 (https=) |
| CN (1) | CN109379891B (https=) |
| AU (1) | AU2017273136B2 (https=) |
| BR (1) | BR112018073521B1 (https=) |
| CA (1) | CA3025720A1 (https=) |
| CY (1) | CY1125589T1 (https=) |
| DK (1) | DK3464265T3 (https=) |
| ES (1) | ES2927779T3 (https=) |
| GB (1) | GB201609607D0 (https=) |
| HR (1) | HRP20221019T1 (https=) |
| HU (1) | HUE059165T2 (https=) |
| IL (1) | IL263222B (https=) |
| LT (1) | LT3464265T (https=) |
| MA (1) | MA45130B1 (https=) |
| MD (1) | MD3464265T2 (https=) |
| MX (1) | MX386113B (https=) |
| PL (1) | PL3464265T3 (https=) |
| PT (1) | PT3464265T (https=) |
| RS (1) | RS63604B1 (https=) |
| RU (1) | RU2756273C2 (https=) |
| SI (1) | SI3464265T1 (https=) |
| SM (1) | SMT202200341T1 (https=) |
| WO (1) | WO2017208005A1 (https=) |
| ZA (1) | ZA201808638B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| GB201910125D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
| CN114667289B (zh) | 2019-09-18 | 2025-08-26 | 武田药品工业有限公司 | 杂芳基血浆激肽释放酶抑制剂 |
| CN111875557B (zh) * | 2020-08-19 | 2023-06-02 | 南通大学 | 一种噻唑类衍生物及其合成方法 |
| US20230381162A1 (en) * | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| JP2024505596A (ja) * | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
| WO2024180100A1 (en) | 2023-02-27 | 2024-09-06 | Kalvista Pharmaceuticals Limited | New solid form of a plasma kallikrein inhibitor |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
| US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
| PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
| WO2001042272A2 (en) | 1999-12-08 | 2001-06-14 | Pharmacia Corporation | Eplerenone crystalline form exhibiting enhanced dissolution rate |
| EP1441734B1 (en) | 2001-10-26 | 2007-02-28 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| AU2002363250A1 (en) | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| KR100755577B1 (ko) | 2002-04-26 | 2007-09-12 | 일라이 릴리 앤드 캄파니 | 타키키닌 수용체 길항제로서의 트리아졸 유도체 |
| EP1426364A1 (en) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Imidazole-derivatives as factor Xa inhibitors |
| DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| US20040192728A1 (en) | 2003-02-03 | 2004-09-30 | Ellen Codd | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| NZ592039A (en) | 2003-08-27 | 2013-03-28 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| MX2007002214A (es) | 2004-09-03 | 2007-05-07 | Yuhan Corp | Derivados de pirrolo[3,2-c]piridina y procesos para su preparacion. |
| EP2500031A3 (en) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions and Methods for Treating Vascular Permeability |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| KR20080023677A (ko) | 2005-04-28 | 2008-03-14 | 갈레니카 테크놀로지 아베 | 지질상을 포함하는 약학적 투약 형태 |
| KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| EA200800321A1 (ru) | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
| US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| CA2655675A1 (en) | 2006-07-06 | 2008-01-10 | Glaxo Group Limited | Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| KR101578674B1 (ko) | 2006-12-29 | 2015-12-18 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 카복스아미드 화합물 및 칼페인 억제제로서의 이의 용도 |
| US20100119512A1 (en) | 2007-01-25 | 2010-05-13 | Joslin Diabetes Center | Methods of diagnosing, treating, and preventing increased vascular permeability |
| AU2008223348A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| DK2142516T3 (da) | 2007-03-30 | 2013-04-15 | Sanofi Sa | Pyrimidinhydrazidforbindelser i ders egenskab af pgds-inhibitorer |
| CA2682649A1 (en) | 2007-04-03 | 2008-10-09 | Glaxo Group Limited | Imidazolidine carboxamide derivatives as p2x7 modulators |
| WO2009012998A1 (en) | 2007-07-26 | 2009-01-29 | Syngenta Participations Ag | Novel microbiocides |
| EP2185506A1 (en) | 2007-08-22 | 2010-05-19 | Allergan, Inc. | Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity |
| CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | METHODS OF TREATING KALLIKREIN RELATED DISORDERS |
| WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| US8324199B2 (en) | 2008-03-13 | 2012-12-04 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| CN102149680B (zh) | 2008-07-08 | 2014-12-10 | 第一三共株式会社 | 含氮芳族杂环化合物 |
| US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| EP2512466A4 (en) | 2009-12-18 | 2013-07-03 | Activesite Pharmaceuticals Inc | PRODRUGS OF INHIBITORS OF PLASMATIC KALLICREIN |
| JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
| ES2569983T3 (es) | 2010-01-28 | 2016-05-13 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serinproteasa de tipo tripsina y su preparación y uso |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| EP2590945B1 (en) | 2010-07-07 | 2014-04-30 | The Medicines Company (Leipzig) GmbH | Serine protease inhibitors |
| US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| EP2458315B1 (de) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung |
| WO2012142308A1 (en) | 2011-04-13 | 2012-10-18 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| EP2718678B1 (en) | 2011-06-08 | 2021-01-27 | Micro Motion, Inc. | Method and apparatus for determining and controlling a static fluid pressure through a vibrating meter |
| US9133128B2 (en) | 2011-06-17 | 2015-09-15 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| EP2760828B1 (en) | 2011-09-27 | 2015-10-21 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| WO2013048982A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| NZ628762A (en) | 2012-02-10 | 2016-07-29 | Constellation Pharmaceuticals Inc | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013130603A1 (en) | 2012-02-27 | 2013-09-06 | Board Of Regents, The University Of Texas System | Ganglioside gd2 as a marker and target on cancer stem cells |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| IL239682B (en) * | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
| CN104918942A (zh) | 2013-01-08 | 2015-09-16 | 萨维拉制药有限公司 | 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| WO2014113712A1 (en) | 2013-01-20 | 2014-07-24 | Dyax Corp. | Evaluation and treatment of bradykinin-mediated disorders |
| CN110179795A (zh) | 2013-03-15 | 2019-08-30 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途 |
| MY174018A (en) | 2013-05-23 | 2020-03-04 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivates |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| CA2920815C (en) | 2013-08-14 | 2021-09-21 | Kalvista Pharmaceuticals Limited | Inhibitors of plasma kallikrein |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| BR112016015449A8 (pt) | 2013-12-30 | 2020-06-09 | Lifesci Pharmaceuticals Inc | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos |
| CN106257976B (zh) | 2014-03-07 | 2021-02-02 | 拜奥克里斯特制药公司 | 人类血浆激肽释放酶抑制剂 |
| WO2015171526A2 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Tricyclic pyrazolopyridine compounds |
| WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| MX381342B (es) | 2014-07-16 | 2025-03-12 | Lifesci Pharmaceuticals Inc | Compuestos terapeuticos inhibidores. |
| US10905683B2 (en) | 2014-08-22 | 2021-02-02 | Biocryst Pharmaceuticals, Inc. | Compositions and uses of amidine derivatives |
| US10189810B2 (en) | 2014-09-17 | 2019-01-29 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| CN107405333A (zh) | 2015-02-27 | 2017-11-28 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| WO2017001926A2 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc | Therapeutic inhibitory compounds |
| WO2017001936A2 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| WO2017072020A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| JP6855477B2 (ja) | 2015-10-27 | 2021-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
| GB201713660D0 (en) | 2017-08-25 | 2017-10-11 | Kalvista Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
| WO2019106359A1 (en) | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201721515D0 (en) | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021032935A1 (en) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| EP4017587A1 (en) | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| WO2021032933A1 (en) | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| CN114286820A (zh) | 2019-08-21 | 2022-04-05 | 卡尔维斯塔制药有限公司 | 酶抑制剂 |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
-
2016
- 2016-06-01 GB GBGB1609607.5A patent/GB201609607D0/en not_active Ceased
-
2017
- 2017-06-01 BR BR112018073521-3A patent/BR112018073521B1/pt active IP Right Grant
- 2017-06-01 MX MX2018014700A patent/MX386113B/es unknown
- 2017-06-01 IL IL263222A patent/IL263222B/en unknown
- 2017-06-01 EP EP17728614.3A patent/EP3464265B1/en active Active
- 2017-06-01 PT PT177286143T patent/PT3464265T/pt unknown
- 2017-06-01 US US16/303,334 patent/US11230537B2/en active Active
- 2017-06-01 MD MDE20190411T patent/MD3464265T2/ro unknown
- 2017-06-01 AU AU2017273136A patent/AU2017273136B2/en active Active
- 2017-06-01 MA MA45130A patent/MA45130B1/fr unknown
- 2017-06-01 LT LTEPPCT/GB2017/051579T patent/LT3464265T/lt unknown
- 2017-06-01 SI SI201731201T patent/SI3464265T1/sl unknown
- 2017-06-01 ES ES17728614T patent/ES2927779T3/es active Active
- 2017-06-01 DK DK17728614.3T patent/DK3464265T3/da active
- 2017-06-01 KR KR1020187038208A patent/KR102425918B1/ko active Active
- 2017-06-01 HR HRP20221019TT patent/HRP20221019T1/hr unknown
- 2017-06-01 RS RS20220860A patent/RS63604B1/sr unknown
- 2017-06-01 SM SM20220341T patent/SMT202200341T1/it unknown
- 2017-06-01 WO PCT/GB2017/051579 patent/WO2017208005A1/en not_active Ceased
- 2017-06-01 PL PL17728614.3T patent/PL3464265T3/pl unknown
- 2017-06-01 HU HUE17728614A patent/HUE059165T2/hu unknown
- 2017-06-01 EP EP22183889.9A patent/EP4151630A1/en active Pending
- 2017-06-01 JP JP2018559929A patent/JP6957516B2/ja active Active
- 2017-06-01 CA CA3025720A patent/CA3025720A1/en active Pending
- 2017-06-01 RU RU2018139276A patent/RU2756273C2/ru active
- 2017-06-01 CN CN201780034393.XA patent/CN109379891B/zh active Active
-
2018
- 2018-12-20 ZA ZA2018/08638A patent/ZA201808638B/en unknown
-
2021
- 2021-10-06 JP JP2021164519A patent/JP7383676B2/ja active Active
- 2021-10-20 US US17/505,906 patent/US11739068B2/en active Active
-
2022
- 2022-09-29 CY CY20221100642T patent/CY1125589T1/el unknown
-
2023
- 2023-07-06 US US18/347,815 patent/US20240199573A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517463A5 (https=) | ||
| RU2018139276A (ru) | Полиморфные модификации n-[(3-фтор-4-метоксипиридин-2-ил)метил]-3-(метоксиметил)-1-({ 4-[(2-оксопиридин-1-ил)метил]фенил} метил)пиразол-4-карбоксамида и их соли | |
| JP2021504310A5 (https=) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2015528798A5 (https=) | ||
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| CN104837833B (zh) | Xia因子抑制剂的晶型 | |
| JP5566907B2 (ja) | Ｎ−（ｔｅｒｔ−ブトキシカルボニル）−３−メチル−ｌ−バリル−（４ｒ）−４−（（７−クロロ−４−メトキシ−１−イソキノリニル）オキシ）−ｎ−（（１ｒ，２ｓ）−１−（（シクロプロピルスルホニル）カルバモイル）−２−ビニルシクロプロピル）−ｌ−プロリンアミドの結晶フォーム | |
| JP2020518581A5 (https=) | ||
| JP2020183408A (ja) | ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用 | |
| JP2019517464A5 (https=) | ||
| JP2019135258A (ja) | 第Ｘａ因子阻害剤の結晶形態 | |
| JP2019509268A5 (https=) | ||
| JP2016505071A5 (https=) | ||
| TW201028428A (en) | Process for producing diamine derivatives | |
| JP2017534662A5 (https=) | ||
| JP2009534373A5 (https=) | ||
| JP2018509426A5 (https=) | ||
| CN103108874A (zh) | 用于制备双嘧达莫的方法 | |
| CN101896477A (zh) | 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途 | |
| JP2016536321A5 (https=) | ||
| CN104086544B (zh) | 阿哌沙班一水合物及其制备方法和药物组合物 | |
| JPWO2020111268A5 (https=) | ||
| CN103408400B (zh) | 一种肌醇晶体及其制备方法和用途 | |
| EP3209661B1 (en) | Process for preparing a polymorph of rivaroxaban |